Moderna to conduct trials for its new mRNA products in Taiwan

12/06/2022 06:23 PM
To activate the text-to-speech service, please first agree to the privacy policy below.
Moderna Senior Vice President Patrick Bergstedt speaks at a news conference in Taipei on Tuesday. CNA photo Dec. 6, 2022
Moderna Senior Vice President Patrick Bergstedt speaks at a news conference in Taipei on Tuesday. CNA photo Dec. 6, 2022

Taipei, Dec. 6 (CNA) Moderna sees Taiwan as a crucial site for clinical trials necessary for refining its mRNA technology, and will include it as a site for its multicenter trials, said Patrick Bergstedt, a senior vice president of Moderna, on Tuesday during his first visit to the country.

The multinational pharmaceutical company has launched an initiative called "mRNA Access," which aims to make its technology platform available for use by researchers worldwide, including those in Taiwan, to facilitate their research into nascent transmissive diseases, Bergstedt said at an event in Taipei.

The company will launch clinical trials of 15 nascent or neglected transmissive diseases in 2023 with an emphasis on respiratory diseases, he said.

The Asia-Pacific region is an indispensable market for Moderna, which in 2021 created subsidiaries in Japan, South Korea and Australia, and in September this year launched a subsidiary in Taiwan, he said.

With the establishment of Moderna Taiwan, the company hopes to tap into the country's world-famous health care system, medical research capacity, and innovations in the biotechnology industry to provide people in Taiwan with more disease prevention and treatment options and collaborate with its health care experts to help the country meet challenges in health care, he said.

Taiwan is the only Asian country that has been tapped by Moderna to conduct clinical research into respiratory diseases and flu vaccines, Moderna Taiwan General Manager Joyce Lee (李宜真) said.

The preliminary results from those studies are expected to become available in March 2023, she said.

Moderna Taiwan General Manager Joyce Lee. CNA photo Dec. 6, 2022
Moderna Taiwan General Manager Joyce Lee. CNA photo Dec. 6, 2022

Moderna supplied more than 800 million doses of mRNA vaccines worldwide in 2021 and is exploring new possibilities for mRNA application outside the field of COVID-19 vaccines, she said.

The company will bring its most advanced mRNA technology to Taiwan to facilitate its clinical trials in the country and to market its mRNA technology, she said.

Meanwhile, Moderna Taiwan has begun recruiting market access, digital marketing, and commercial specialists as it seeks to expand its staff to 10 in 2023, she said.

(By Han Ting-ting and Sean Lin)

Enditem/HY

> Chinese Version

Related News

Dec. 1: Taiwan receives new shipment of Moderna vaccine against Omicron BA.5

Oct. 26: Taiwan grants EUA for updated Pfizer and Moderna COVID-19 vaccines

Sept. 30: Moderna establishes Taiwan unit to enhance cooperation

Sept. 2: Taiwan grants EUA for new Moderna COVID-19 vaccine aginst BA.1

    0:00
    /
    0:00
    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.